Hence, the current study was designed to determine the circulating levels of GZB in patients with ACS being compared with healthy control subjects.
The second aliquot was collected on EDTA for GZB and FKN assay.
Plasma GZB was assayed using Wkea Med Supplies Corp., NY, USA ELISA kit and plasma FKN ELISA kit was supplied by R&D Systems, Inc, Minneapolis, MN, USA.
Multiple stepwise regression analysis was done to identify risk factors that contribute to plasma GZB levels.
Serum levels of hsCRP, GZB, IL-18, and FKN showed significant elevation in ACS group when compared to the healthy control group at P < 0.001 (Table 1).
Changes in hsCRP, GZB, IL-18, and FKN Levels in ACS Groups.
Correlations between IL-18, GZB, and FKN Among Each Other and with Clinical Parameters of ACS Patients.
For the clinical parameters of ACS patients, as depicted in Table 4, correlation analyses also revealed significant correlations between GZB and SBP, DBP, peak CK, and peak CK-MB.
Effect of Cardiovascular Risk Factors on Plasma GZB Levels in ACS Patients.
Since extracellular GZB was discovered, several in vitro studies have been done to verify its mechanisms of action but only a limited number of clinical studies evaluated its role as a circulating biomarker for cardiovascular diseases [21-23].